Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 8 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2020 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 31, 2021 |
|
| Operating expenses: | ||||||
| Research and development | $ 381,566 | $ 1,532,782 | $ 1,707,367 | $ 5,037,429 | $ 4,249,326 | $ 6,914,756 |
| General and administrative | 817,898 | 1,511,165 | 823,179 | 4,608,755 | 3,844,212 | 5,035,729 |
| Total operating expenses | 1,199,464 | 3,043,947 | 2,530,546 | 9,646,184 | 8,093,538 | 11,950,485 |
| Loss from operations | (1,199,464) | (3,043,947) | (2,530,546) | (9,646,184) | (8,093,538) | (11,950,485) |
| Other income (expense): | ||||||
| Other income (expense) | 28,728 | (557) | 84 | 24,221 | (32,913) | (36,352) |
| Total other income (expense), net | 28,728 | (557) | 84 | 24,221 | (32,913) | (36,352) |
| Net loss | $ (1,170,736) | $ (3,044,504) | $ (2,530,462) | $ (9,621,963) | $ (8,126,451) | $ (11,986,837) |
| Net loss per share, basic (in Dollars per share) | $ (0.06) | $ (0.48) | $ (1.58) | $ (0.57) | $ (3.83) | $ (5.19) |
| Weighted-average shares used to compute net loss per share, basic (in Shares) | 21,055,211 | 6,291,690 | 1,605,734 | 16,805,082 | 2,120,276 | 2,308,704 |
| Pro-forma net loss per share attributable to common stockholders, basic (unaudited) (in Dollars per share) | $ (1.13) | $ (3.31) | ||||
| Pro-forma weighted-average shares used to compute pro-forma net loss per share, basic (unaudited) (in Shares) | 2,234,664 | 3,622,084 | ||||
| X | ||||||||||
- Definition Pro Forma Basic Earnings Per Share Adjustment to reconcile between Net Income and Pro Forma. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering. No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|